Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intarcia

- PMLiVE

Merck’s Keytruda beats BMS’ Yervoy in melanoma face-off

Both firms competing for a leading share in the highly competitive skin cancer drug market

- PMLiVE

Novo Nordisk sheds autoimmune portfolio to BMS

Continues the trend of pharma buying up unwanted assets from rival firms

- PMLiVE

Lilly/Boehringer’s diabetes combination Glyxambi debuts in US

Companieslaunch first fixed-dose of empagliflozin and linagliptin

Sanofi reception

Type 1 diabetes market to double to $13.6bn

New treatments will see this growth by 2023, according to GlobalData

- PMLiVE

Merck faces another Bridion knockback

It is seven years since the FDA initially rejected it

- PMLiVE

AstraZeneca bullish on diabetes franchise fortunes

Other big pharma firms face a difficult 2015, but AZ is confident it won't

- PMLiVE

Keytruda is UK’s first early-access medicine

Merck’s melanoma therapy accepted under the UK’s EAMS

UK flag

Type 1 diabetes vaccine possible ‘within a generation’

Follows the injection of a new funding stream for its research

- PMLiVE

Novo’s Tresiba reduces risk of hypoglycaemia

New clinical data on the diabetes drug also shows blood glucose control benefits

- PMLiVE

Quality in Care’s 2015 diabetes programme launches at Diabetes UK

Now open for entries to celebrate best practice in NHS diabetes care

UK flag

NHS staff blame cost-cutting for poor diabetes outcomes

Lack of local and national leadership also cited in new ABPI report

- PMLiVE

Merck and Eisai link up on anti-PD-1 combinations

Will test Keytruda with both Lenvima and Halaven 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links